CHICAGO ¨C Takeda Pharmaceutical Co.¡¯s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue.
Takeda¡¯s vaccine was 80.2 percent effective at preventing dengue among children and teens in the year after they got the shot, according to results of a Phase III study published in the New England Journal of Medicine on Wednesday.
Sanofi¡¯s Dengvaxia ¡ª the world¡¯s first dengue vaccine ¡ª had demonstrated 59.2 percent overall efficacy in the first year of follow-up based on combined results from two late stage trials.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.